Predictive Oncology Inc (POAI)

[Paullee]

Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer


More content below
Predictive Oncology Inc.
Mon, February 8, 2021, 8:30 AM


More content below

POAI
-5.00%
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL™. The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. This process will generate data on which compounds are active against which specific patient profile(s), delivering both proof data for the PeDAL approach and valuable Intellectual Property (IP) for the company.

“With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are very excited to kick-off this first project focused on ovarian cancer. Our expectations are that the project will have significant value by generating proof data for our PeDAL approach, which will be useful in our commercial discussions with Pharmaceutical companies. In addition, the project will also demonstrate the long-term value of Helomics unique data,” explained Dr. Carl Schwartz, CEO of Predictive Oncology.

“Looking forward, we strongly believe successful execution of this project will demonstrate that Predictive Oncology is emerging as a leader in AI-driven drug discovery,” commented Dr. Schwartz.